الفهرس 
Historical Overview of Hodgkin’s LymphomaOnly 14 pages are availabe for public view
 |  | from | 177 |  |  |
| | | from | 177 | | |
Abstract
Hodgkin’s disease (HD) is a type of Lymphoma, it is an uncommon malignant tumor of the lymphatic system slightly less than 1% of all cancers worldwide, represents about 10% of all Lymphomas & characterized by Reed–Sternberg (RS) giant cells that replace normal lymphoid structure & characterized clinically by the orderly spread of disease from one lymph node group to another and by the development of systemic symptoms with advanced disease. Because the goal in treating lymphoma is most often cure rather than palliation, meticulous approach to diagnosis, and staging is mandatory, fortunately advances in immunophenotyping, cytogenetics and molecular biology can provide help in situation that diagnosis was previously impossible. Hodgkin lymphoma was one of the first cancers to be cured by radiation. Later it was one of the first to be cured by combination chemotherapy. PET/CT scan plays an important role in staging & monitoring, as it is the examination of choice for detecting disease activity after treatment compared with CT scan alone. PET/CT scanning is better able to distinguish between active tumor and necrosis or fibrosis in residual masses, it is also used mid treatment & it was clear that it can provide prognostic information as patients with positive interim PET/CT has poor prognosis. Also freedom from disease progression was statistically lower in patients who had positive PET scans after chemotherapy. High dose chemotherapy & Stem cell transplantation play an important role in the treatment, especially refractory & relapsed disease , not only but also may be used after 1st complete remission in high risk advanced patients. Targeted therapy also used in Hodgkin Lymphoma such as unconjugated anti-CD30 antibodies are well tolerated in HL showing only moderate activity in refractory and relapsed Patients. Anti CD 20 is also used in Lymphocytic Predominance type. As for Immunotoxins as Ricin A, they are used in relapsed & refractory cases while Radioimmunotherapy with Yttrium 90 or Iodine131-labeled polyclonal antiferritine antibodies in relapsed and refractory patients led to remission rates between 20 – 80 %.